ArticleTissue engineering and regenerative medicine2026
Cord Blood Platelet-Poor Plasma Functionalizes Polycaprolactone Scaffolds for Coupled Vascularization and Osteogenesis in Bone Tissue Engineering.
Article in Tissue engineering and regenerative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundAngiogenesis is critical for the success of 3D scaffolds in bone tissue engineering. This study investigated the use of platelet-poor plasma (PPP) derived from umbilical cord blood (UCB) as a bioactive coating agent to impart osteo-inductive, angiogenic, and immunomodulatory properties to 3D-printed polycaprolactone (PCL) scaffolds.
methodsPCL scaffolds were coated with UCB-PPP and evaluated in vitro for cell adhesion, proliferation, extracellular matrix (ECM) expression, and osteogenic differentiation of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) and fibroblasts (hFBs). In vitro angiogenesis was evaluated via the tube formation of human umbilical vein-derived endothelial cells. In vivo neovascularization and tissue integration were assessed using a subcutaneous mouse implantation model, alongside immunogenicity testing using rat and human allogeneic mononuclear cells.
resultsThe PPP coating proved highly effective, enhancing adhesion and proliferation of hUC-MSCs and hFBs by upregulating ECM components and pro-regenerative cytokines. In vitro, PPP coating promoted osteoblast differentiation of hUC-MSCs, as evidenced by increased calcium deposition and expression of osteoprogenitor markers. Crucially, the PPP coating stimulated robust in vitro tube formation and in vivo subcutaneous neovascularization, evidenced by functional, erythrocyte-perfused endothelial lumens, elevated VEGF-A expression, and M2 macrophage polarization. Moreover, PPP-coated scaffolds demonstrated low immunogenicity in both rat and human allogeneic mononuclear cells, thereby supporting preclinical safety and immunomodulation.
conclusionsUCB-PPP serves as an immune-tolerant, highly bioactive coating that functionalizes inert PCL scaffolds by promoting in vitro osteogenesis and in vivo functional vascular integration. This dual-action strategy provides a promising proof-of-concept for addressing vascularization bottlenecks in bone tissue engineering applications.
Indexed as
Identifiers
42814314What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.